Reviva Pharmaceuticals Schizophrenia Drug Demonstrates Strong Efficacy On Heels Of Bristol Myers, FDA Approval: Analyst
Reviva Pharmaceuticals Schizophrenia Drug Demonstrates Strong Efficacy On Heels Of Bristol Myers, FDA Approval: Analyst
Last month, Reviva Pharmaceuticals released new vocal biomarker data from the Phase 3 RECOVER trial of brilaroxazine in schizophrenia.Last week, the FDA approved Bristol Myers Squibb & Co's (NYSE:BMY) Cobenfy (xanomeline and trospium chloride, KarXT), an oral medication for schizophrenia in adults.
上週，FDA批准了Bristol Myers Squibb（紐交所：BMY）的Cobenfy（xanomeline和trospium chloride，KarXT），這是一種針對成年人精神分裂症的口服藥物。
Analysts at investment bank EF Hutton says, "This bodes well for Reviva's Brilaroxazine, a multi-receptor-targeting antipsychotic that primarily focuses on serotonin (5-HT2A, 5-HT7), dopamine (D2, D3), and adrenergic receptors."
投資銀行EF Hutton的分析師表示：「這對Reviva的Brilaroxazine是個好兆頭，這是一種以5-羥色胺（5-HT2A、5-HT7）、多巴胺（D2、D3）和腎上腺素受體爲主要靶點的多受體靶向抗精神病藥物。」
Reviva Pharmaceuticals Holdings, Inc.'s (NASDAQ:RVPH) pipeline currently includes two drug candidates, brilaroxazine (RP5063) and RP1208.
reviva pharmaceuticals控股公司（納斯達克：RVPH）目前的產品線包括兩種藥物候選品，brilaroxazine（RP5063）和RP1208。
Last month, Reviva Pharmaceuticals released new vocal biomarker data from the Phase 3 RECOVER trial of brilaroxazine in schizophrenia.
上個月，Reviva Pharmaceuticals發佈了brilaroxazine在精神分裂症RECOVER第三階段試驗中的新聲音生物標誌數據。
Brilaroxazine demonstrated a strong efficacy for negative symptoms and other key symptoms of schizophrenia, such as total and positive symptoms, disorganization, and social functioning in the pivotal phase 3 RECOVER trial in schizophrenia.
在重要的第三階段精神分裂症RECOVER試驗中，brilaroxazine表現出對於負性症狀和其他關鍵症狀（如總體和陽性症狀、紊亂和社會功能）的強效性。
The analyst notes that while Cobenfy primarily acts as a dopamine D2 partial agonist with limited serotonin receptor involvement, Brilaroxazine targets a broader range of receptors. This expanded activity could have a wider therapeutic impact, especially on cognitive symptoms.
分析師指出，儘管Cobenfy主要作爲多巴胺D2部分激動劑，涉及到的5-羥色胺受體有限，而Brilaroxazine則針對更廣泛的受體。這種擴增活性可能會產生更廣泛的治療影響，尤其是在認知症狀方面。
The analyst further highlights that both Cobenfy and Brilaroxazine are effective in addressing the positive and negative symptoms of schizophrenia. However, Brilaroxazine's action on the 5-HT7 receptor, which plays a crucial role in cognition, may offer added benefits in cognitive enhancement.
分析師進一步強調，Cobenfy和Brilaroxazine都有效地針對精神分裂症的陽性和負性症狀。不過，Brilaroxazine對5-HT7受體的作用，這在認知中扮演重要角色，可能提供認知增強的附加好處。
In terms of side effects, Cobenfy presents a more typical profile for second-generation antipsychotics, including risks of weight gain and metabolic issues. Brilaroxazine, on the other hand, is being developed to mitigate these metabolic concerns and minimize movement-related side effects.
就副作用而言，Cobenfy呈現出更典型的第二代抗精神病藥物特徵，包括體重增加和代謝問題的風險。另一方面，Brilaroxazine正在開發以減輕這些代謝問題並將運動相關副作用最小化。
The analyst concludes that Cobenfy and Brilaroxazine take distinct paths in treating schizophrenia. Both therapies offer value in the treatment landscape, but Brilaroxazine's potential cognitive advantages and improved metabolic profile could give it an edge upon approval.
分析師得出結論，Cobenfy和Brilaroxazine在治療精神分裂症方面採取不同的路徑。這兩種療法在治療領域中都提供了價值，但Brilaroxazine潛在的認知優勢和改善的代謝特性可能在獲批後使其具備優勢。
Price Action: Reviva Pharmaceuticals stock is down 4.8% at $1.19 at last check Monday.
股價走勢：reviva pharmaceuticals股票最新報價下跌4.8%，報1.19美元，截至上週一最後查看。
Read next:
閱讀下一篇：
- What's Going On With Trump Media & Technology Stock On Monday?
- 週一特朗普媒體科技股票發生了什麼？
譯文內容由第三人軟體翻譯。
